This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
healthcare: Archive
UnitedHealth vs. Humana: Which Healthcare Stock Has More Upside Now?
by Rajshree Sipani
UNH's scale and diversified model are likely to offer stronger upside than HUM as rising medical costs test managed care margins.
UNHPositive Net Change HUMNegative Net Change
artificial-intelligence healthcare hmo insurance insurance-premium medical smart-health
UnitedHealth's Q4 Beat Can't Stop the Slide: Should You Let Go Now?
by Kaibalya Pravo Dey
UNH beats Q4 EPS, but the stock plunges 21.5% as medical costs spiked, margins sank, and Medicare reimbursement risk clouded its outlook.
UNHPositive Net Change MOHNegative Net Change CNCNegative Net Change
earnings-report earnings-surprise healthcare hmo insurance insurance-premium medical
Silver Economy Boom: Investing in Healthcare's Aging Tailwinds
by Urmimala Biswas
An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.
ABTNegative Net Change BSXNegative Net Change AMGNNegative Net Change MDTPositive Net Change RMDPositive Net Change ABBVPositive Net Change
biotechs cancer healthcare hospitals medical medical-devices pharmaceuticals
Is UnitedHealth Group (UNH) a 'Buy' Ahead of Its Upcoming Earnings Announcement?
by Bryan Hayes
Elevated debt and interest expenses are straining the company's financial flexibility.
UNHPositive Net Change
earnings healthcare hmo insurance investing large-cap medical stock-performance
UNH vs. ELV: Which Managed Care Stock Has the Edge Today?
by Rajshree Sipani
Elevance Health is edging past UnitedHealth as Carelon's growth, strategic exits and a cheaper valuation shape a stronger near-term setup.
UNHPositive Net Change ELVNegative Net Change
artificial-intelligence dental finance healthcare hospitals insurance insurance-premium medical smart-health
The Longevity Shift: Healthcare REITs to Benefit From Global Aging
by Urmimala Biswas
WELL, VTR, CTRE and OHI are tapping the longevity economy as aging populations drive rising demand for senior housing, skilled nursing and long-term care real estate.
VTRPositive Net Change OHINegative Net Change CTREPositive Net Change WELLPositive Net Change
finance healthcare medical medical-devices
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
by Urmimala Biswas
Tempus AI's Q3 revenue surged as oncology and hereditary testing led the way, margins improved, and pricing tailwinds and regulatory milestones took shape.
TXGPositive Net Change DOCSPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-growth earnings-outlook healthcare medical medical-devices
Tempus AI Near $75 Target? Valuation, Upside and Risks
by Urmimala Biswas
Tempus AI's rally meets a $75 target. Here's how valuation, catalysts, risks, and key numbers set up the risk-reward into 2026.
TXGPositive Net Change DOCSPositive Net Change TEMPositive Net Change
artificial-intelligence healthcare medical medical-devices
Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run?
by Urmimala Biswas
Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.
IQVNegative Net Change GHNegative Net Change TEMPositive Net Change
artificial-intelligence earnings-report healthcare medical medical-devices valuation
Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook
by Urmimala Biswas
Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.
ILMNNegative Net Change GHNegative Net Change TEMPositive Net Change
artificial-intelligence earnings-report healthcare medical medical-devices